诊断放射性同位素市场报告：趋势、预测和竞争分析（至 2031 年）

全球诊断放射性同位素市场未来前景光明，在医院、专科诊所、诊断中心、学术和研究机构市场都机会。预计到 2031 年全球诊断放射性同位素市场规模将达到 69 亿美元，2025 年至 2031 年的复合年增长率为 6.7%。该市场的关键驱动因素是对疾病早期和准确诊断的需求不断增长、诊断显像模式的进步以及对α发射同位素的需求不断增长。

• Lucintel 预测，基于放射性同位素的Technetium-99m 部分将在预测期内经历最高的增长。
• 在最终用途类别中，预计专科诊所将在预测期内见证最高成长。
• 按地区划分，北美将在预测期内继续成为最大的地区。

诊断放射性同位素市场的策略性成长机会

由于技术、生产和诊断技术的进步，诊断放射性同位素市场为关键应用提供了多种策略成长机会。

• PET 影像在肿瘤学中的扩展：PET 影像在癌症诊断中的广泛应用代表着一个巨大的成长机会。扩大 PET 放射性同位素的使用范围将改善早期癌症的检测和治疗计划。
• 混合成像技术的发展：对混合 PET-CT 和 PET-MRI 技术的投资将透过提供更精确的诊断工具提供成长机会。这些系统使医疗保健提供者能够提高癌症和心血管疾病等复杂疾病的诊断准确性。
• 非铀同位素产量增加：非铀基诊断同位素的生产具有成长潜力。开发这些技术有助于缓解环境问题并提供更永续和可靠的同位素供应。
• 扩展到新兴市场：扩大新兴市场的医疗保健基础设施，特别是亚洲和拉丁美洲，为扩大诊断放射性同位素的生产和取得提供了机会。此次扩展将有助于解决医疗保健不平等问题并提高服务不足地区的诊断能力。
• 投资低剂量成像技术：减少辐射暴露的放射性同位素成像技术的开发代表着一个成长机会。这些创新将使诊断成像更加安全，并鼓励其广泛应用于更早、更频繁的诊断。

这些策略性成长机会凸显了诊断放射性同位素领域的技术创新和市场扩张的潜力。专注于 PET 成像、混合系统、非铀同位素生产、新兴市场和低剂量技术将使公司推动成长并改善患者的治疗效果。

诊断放射性同位素市场驱动因素与挑战

诊断放射性同位素市场受到各种驱动因素​​和挑战的影响，这些驱动因素和挑战决定了其成长和发展。了解这些因素对于有效驾驭市场至关重要。

推动诊断放射性同位素市场的因素有：

• 早期疾病检测需求不断增加：对癌症和心血管疾病等疾病早期检测的重视程度不断提高，推动了对诊断放射性同位素的需求，尤其是 PET 和 SPECT 同位素。
• 成像技术的进步：混合系统和人工智慧整合等成像技术的创新正在提高诊断的准确性并鼓励进一步采用基于放射性同位素的诊断方法。
• 全球老化：随着全球人口老化，慢性病盛行率增加，推动了依赖放射性同位素进行早期检测和监测的诊断影像的需求。
• 增加政府支持：世界各国政府都在投资核子医学研究和放射性同位素生产，以确保诊断同位素的稳定供应，特别是在努力实现医疗自给自足的国家。
• 扩大非铀生产的使用：受环境问题和确保Technetium-99m等关键同位素稳定供应链的愿望的推动，向非铀基同位素生产的转变正在获得动力。

诊断放射性同位素市场的挑战包括：

• 放射性同位素生产成本高：生产诊断放射性同位素的成本过高，尤其是透过迴旋加速器生产等先进方法，这可能会限制某些地区的取得并影响市场扩张。
• 供应链中断：诊断同位素的全球供应链可能脆弱，生产中断可能影响Technetium-99m等关键同位素的可得性，导致诊断程序延迟。
• 监管障碍：对放射性同位素的生产、处理和处置的严格监管要求可能会减缓市场成长，尤其是在核能法规复杂的地区。

诊断放射性同位素市场受到技术进步、对早期检测疾病的需求不断增长以及政府支持不断增加的推动。但他们也必须应对生产成本上升、供应链中断、监管障碍以及新兴市场进入限制等问题。平衡这些市场驱动因素和挑战是维持市场成长的关键。

目录

第一章执行摘要

第 2 章。

• 简介、背景和分类
• 供应链
• 产业驱动因素与挑战

第 3 章 市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）与预测（2025-2031）
• 全球诊断放射性同位素市场趋势（2019-2024 年）及预测（2025-2031 年）
• 全球诊断放射性同位素市场（以放射性同位素划分）
  • Technetium-99m
  • 铊-201
  • 镓-67
  • 碘-123
  • FDG
  • 铷 82
  • 其他的
• 全球诊断放射性同位素市场（以显像模式）
  • SPECT
  • PET
  • 贝塔发射体
• 全球诊断放射性同位素市场（按应用）
  • 诊断
  • 治疗
• 全球诊断放射性同位素市场（按最终用途划分）
  • 医院
  • 专科门诊
  • 诊断中心
  • 学术研究所
  • 其他的

第 4 章区域市场趋势与预测分析（2019-2031 年）

• 全球诊断放射性同位素市场（按地区）
• 北美诊断放射性同位素市场
• 欧洲诊断放射性同位素市场
• 亚太地区诊断放射性同位素市场
• 世界其他地区诊断放射性同位素市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球诊断放射性同位素市场成长机会（以放射性同位素）
  • 全球诊断放射性同位素市场按显像模式分類的成长机会
  • 全球诊断放射性同位素市场成长机会（按应用）
  • 全球诊断放射性同位素市场成长机会（按最终用途划分）
  • 全球诊断放射性同位素市场各区域成长机会
• 全球诊断放射性同位素市场的新趋势
• 战略分析
  • 新产品开发
  • 扩大全球诊断放射性同位素市场的产能
  • 全球诊断放射性同位素市场的企业合併
  • 认证和许可

第七章主要企业简介

• GE Healthcare
• Siemens Healthineers
• Koninklijke Philips
• Cardinal Health
• Lantheus Holdings
• Bayer
• Bracco
• Eckert & Ziegler

The future of the global diagnostic radioisotope market looks promising with opportunities in the hospital, specialty clinic, diagnostic center, and academic & research institute markets. The global diagnostic radioisotope market is expected to reach an estimated $6.9 billion by 2031 with a CAGR of 6.7% from 2025 to 2031. The major drivers for this market are the increasing demand for early and accurate diagnosis of diseases, growing advancements in diagnostics imaging modalities, and expanding demand for alpha radioisotopes.

• Lucintel forecasts that, within the radioisotope category, the technetium-99m segment is expected to witness the highest growth over the forecast period.
• Within the end use category, specialty clinic is expected to witness the highest growth over the forecast period.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Diagnostic Radioisotope Market

The diagnostic radioisotope market is evolving, driven by advancements in technology, improved production methods, and increased demand for precise diagnostic tools in healthcare.

• Growing Demand for PET Imaging: The use of PET imaging is expanding due to its effectiveness in detecting cancer and neurological disorders. This trend is increasing the demand for PET radioisotopes like FDG, which are essential for accurate diagnosis.
• Non-Uranium-Based Production: There is a growing shift toward non-uranium-based methods for producing diagnostic radioisotopes. These methods are safer and more sustainable, reducing environmental concerns while ensuring a reliable supply for medical use.
• Hybrid Imaging Systems: The integration of PET with CT or MRI is becoming more common, offering improved diagnostic accuracy. This trend is reshaping diagnostic practices, particularly in cancer, cardiovascular, and neurological imaging.
• Focus on Reducing Radiation Exposure: New advancements aim to reduce the radiation dose patients receive during diagnostic procedures. This trend improves patient safety, making radioisotope-based imaging a more appealing option for frequent and early-stage diagnostics.
• Increased Self-Sufficiency in Production: Countries are focusing on becoming self-sufficient in radioisotope production to avoid supply chain disruptions. This trend is driving investments in local facilities and technologies to produce essential diagnostic isotopes domestically.

These trends are reshaping the diagnostic radioisotope market by enhancing diagnostic capabilities, improving safety, and addressing global supply chain concerns. The growing use of PET imaging, hybrid systems, and sustainable production methods is driving innovation and expanding the market's reach.

Recent Developments in the Diagnostic Radioisotope Market

Key developments in the diagnostic radioisotope market reflect technological advancements and strategic investments aimed at improving isotope availability and diagnostic accuracy.

• Non-Uranium Production Methods: The adoption of non-uranium-based production for Technetium-99m is reducing reliance on uranium, ensuring a more sustainable supply chain, and improving global access to this critical diagnostic isotope.
• Expansion of PET Isotope Production: Countries like China and India are increasing PET isotope production, particularly FDG, which is essential for cancer diagnostics. These developments are helping to meet the rising demand for PET imaging in oncology.
• Development of Hybrid Imaging Systems: The introduction of hybrid PET-CT and PET-MRI systems in countries like Germany is enhancing diagnostic precision, particularly in complex cases such as cancer metastasis, cardiovascular disease, and neurological disorders.
• Collaborative Research and Production: In India, collaborations between hospitals and research institutions are improving access to diagnostic radioisotopes, particularly in underserved regions. These partnerships aim to address healthcare inequalities and enhance diagnostic services.
• Reduction in Radiation Dose: Japan is at the forefront of reducing radiation exposure in radioisotope imaging, focusing on innovations that maintain image quality while minimizing the risks associated with radiation.

These developments are advancing the diagnostic radioisotope market by improving production methods, enhancing diagnostic precision, and making radioisotope imaging safer and more accessible. The focus on sustainability, technological innovation, and collaboration is driving growth in the market.

Strategic Growth Opportunities for Diagnostic Radioisotope Market

The diagnostic radioisotope market offers several strategic growth opportunities across key applications, driven by advancements in technology, production, and diagnostic techniques.

• Expansion of PET Imaging in Oncology: The increasing use of PET imaging for cancer diagnostics presents a major growth opportunity. Expanding access to PET radioisotopes can improve early cancer detection and treatment planning.
• Development of Hybrid Imaging Technologies: Investing in hybrid PET-CT and PET-MRI technologies offers growth opportunities by providing more precise diagnostic tools. These systems enable healthcare providers to improve accuracy in diagnosing complex conditions like cancer and cardiovascular disease.
• Increased Production of Non-Uranium Isotopes: There is potential for growth in the production of non-uranium-based diagnostic isotopes. Developing these technologies can reduce environmental concerns and provide a more sustainable and reliable isotope supply.
• Expansion into Emerging Markets: Growing healthcare infrastructure in emerging markets, particularly in Asia and Latin America, presents opportunities for expanding diagnostic radioisotope production and access. This expansion can address healthcare inequalities and improve diagnostic capabilities in underserved areas.
• Investment in Low-Dose Imaging Technologies: Developing radioisotope imaging technologies that reduce radiation exposure presents a growth opportunity. These innovations can make diagnostic imaging safer, encouraging broader adoption for early and frequent diagnostics.

These strategic growth opportunities highlight the potential for innovation and market expansion in the diagnostic radioisotope sector. By focusing on PET imaging, hybrid systems, non-uranium isotope production, emerging markets, and low-dose technologies, companies can drive growth and improve patient outcomes.

Diagnostic Radioisotope Market Driver and Challenges

The diagnostic radioisotope market is influenced by various drivers and challenges that shape its growth and development. Understanding these factors is essential for navigating the market effectively.

The factors responsible for driving the diagnostic radioisotope market include:

• Rising Demand for Early Disease Detection: The growing emphasis on early detection of diseases like cancer and cardiovascular conditions is driving demand for diagnostic radioisotopes, particularly PET and SPECT isotopes.
• Technological Advancements in Imaging: Innovations in imaging technologies, such as hybrid systems and AI integration, are improving diagnostic accuracy, driving further adoption of radioisotope-based diagnostics.
• Global Aging Population: As the global population ages, the prevalence of chronic diseases increases, fueling the demand for diagnostic imaging procedures that rely on radioisotopes for early detection and monitoring.
• Increased Government Support: Governments worldwide are investing in nuclear medicine research and radioisotope production to ensure a stable supply of diagnostic isotopes, particularly in countries aiming for healthcare self-sufficiency.
• Growing Use of Non-Uranium Production: The shift toward non-uranium-based isotope production is gaining momentum, driven by environmental concerns and the desire to secure a stable supply chain for key isotopes like Technetium-99m.

Challenges in the diagnostic radioisotope market are:

• High Cost of Radioisotope Production: The cost of producing diagnostic radioisotopes, particularly through advanced methods like cyclotron production, can be prohibitive, limiting access in certain regions and affecting market expansion.
• Supply Chain Disruptions: The global supply chain for diagnostic isotopes can be fragile, with production disruptions affecting the availability of key isotopes like Technetium-99m, leading to delays in diagnostic procedures.
• Regulatory Hurdles: Strict regulatory requirements for the production, handling, and disposal of radioisotopes can slow down market growth, particularly in regions with complex nuclear regulations.

The diagnostic radioisotope market is driven by technological advancements, rising demand for early disease detection, and increasing government support. However, challenges such as high production costs, supply chain disruptions, regulatory hurdles, and limited access in emerging markets must be addressed. Balancing these drivers and challenges is key to sustaining growth in the market.

List of Diagnostic Radioisotope Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies diagnostic radioisotope companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the diagnostic radioisotope companies profiled in this report include-

• GE Healthcare
• Siemens Healthineers
• Koninklijke Philips
• Cardinal Health
• Lantheus Holdings
• Bayer
• Bracco
• Eckert & Ziegler
• Nordion
• NTP Radioisotopes

Diagnostic Radioisotope by Segment

The study includes a forecast for the global diagnostic radioisotope market by radioisotope, imaging modality, application, end use, and region.

Diagnostic Radioisotope Market by Radioisotope [Analysis by Value from 2019 to 2031]:

• Technetium-99m
• Thallium-201
• Gallium-67
• Iodine-123
• FDG
• Rubidium-82
• Others

Diagnostic Radioisotope Market by Imaging Modality [Analysis by Value from 2019 to 2031]:

• SPECT
• PET
• Beta Emitters

Diagnostic Radioisotope Market by Application [Analysis by Value from 2019 to 2031]:

• Diagnostic
• Therapeutic

Diagnostic Radioisotope Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Academic & Research Institutes
• Others

Diagnostic Radioisotope Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Diagnostic Radioisotope Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below image highlights recent developments by major diagnostic radioisotope producers in key regions: the USA, China, India, Japan, and Germany

• United States: The U.S. is advancing the production of Technetium-99m, the most widely used radioisotope in diagnostics. Recent developments include the establishment of non-uranium-based production facilities, which enhance the supply chain and reduce dependence on imported isotopes, ensuring a stable supply for medical imaging.
• China: China is increasing its capacity for radioisotope production, focusing on expanding the use of PET (Positron Emission Tomography) imaging. Recent developments include new cyclotrons to produce fluorodeoxyglucose (FDG) for PET scans, aimed at improving cancer diagnostics and broader healthcare access.
• Germany: In Germany, advancements in diagnostic radioisotope technologies focus on the development of hybrid imaging systems that combine PET with CT or MRI. These innovations improve diagnostic accuracy, particularly in oncology, cardiology, and neurology, enhancing patient outcomes through more precise imaging.
• India: India has made significant strides in self-sufficiency for radioisotope production, with the government investing in new research reactors. Recent developments include collaborations between hospitals and research institutions to increase the availability of radioisotopes for diagnostic purposes, particularly in rural and underserved areas.
• Japan: Japan is leveraging technological innovations to enhance the production and use of diagnostic radioisotopes. Recent developments focus on reducing radiation doses in medical imaging, improving patient safety while maintaining high imaging quality, especially in cancer detection and cardiovascular diagnostics.

Features of the Global Diagnostic Radioisotope Market

Market Size Estimates: Diagnostic radioisotope market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Diagnostic radioisotope market size by various segments, such as by radioisotope, imaging modality, application, end use, and region in terms of value ($B).

Regional Analysis: Diagnostic radioisotope market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different radioisotopes, imaging modalities, applications, end uses, and regions for the diagnostic radioisotope market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the diagnostic radioisotope market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the diagnostic radioisotope market by radioisotope (technetium-99m, thallium-201, gallium-67, iodine-123, FDG, rubidium-82, and others), imaging modality (SPECT, PET, and beta emitters), application (diagnostic and therapeutic), end use (hospitals, specialty clinics, diagnostic centers, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Diagnostic Radioisotope Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Diagnostic Radioisotope Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Diagnostic Radioisotope Market by Radioisotope
  • 3.3.1: Technetium-99m
  • 3.3.2: Thallium-201
  • 3.3.3: Gallium-67
  • 3.3.4: Iodine-123
  • 3.3.5: FDG
  • 3.3.6: Rubidium-82
  • 3.3.7: Others
• 3.4: Global Diagnostic Radioisotope Market by Imaging Modality
  • 3.4.1: SPECT
  • 3.4.2: PET
  • 3.4.3: Beta Emitters
• 3.5: Global Diagnostic Radioisotope Market by Application
  • 3.5.1: Diagnostic
  • 3.5.2: Therapeutic
• 3.6: Global Diagnostic Radioisotope Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Specialty Clinics
  • 3.6.3: Diagnostic Centers
  • 3.6.4: Academic & Research Institutes
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Diagnostic Radioisotope Market by Region
• 4.2: North American Diagnostic Radioisotope Market
  • 4.2.1: North American Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.2.2: North American Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others
• 4.3: European Diagnostic Radioisotope Market
  • 4.3.1: European Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.3.2: European Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others
• 4.4: APAC Diagnostic Radioisotope Market
  • 4.4.1: APAC Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.4.2: APAC Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others
• 4.5: ROW Diagnostic Radioisotope Market
  • 4.5.1: ROW Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.5.2: ROW Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Diagnostic Radioisotope Market by Radioisotope
  • 6.1.2: Growth Opportunities for the Global Diagnostic Radioisotope Market by Imaging Modality
  • 6.1.3: Growth Opportunities for the Global Diagnostic Radioisotope Market by Application
  • 6.1.4: Growth Opportunities for the Global Diagnostic Radioisotope Market by End Use
  • 6.1.5: Growth Opportunities for the Global Diagnostic Radioisotope Market by Region
• 6.2: Emerging Trends in the Global Diagnostic Radioisotope Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Diagnostic Radioisotope Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Diagnostic Radioisotope Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GE Healthcare
• 7.2: Siemens Healthineers
• 7.3: Koninklijke Philips
• 7.4: Cardinal Health
• 7.5: Lantheus Holdings
• 7.6: Bayer
• 7.7: Bracco
• 7.8: Eckert & Ziegler